2783-72-4

Basic information

• Product Name: 3-methyl-2-[(Z)-(3-methyl-1,3-benzothiazol-2(3H)-ylidene)methyl]-1,3-benzothiazol-3-ium iodide
• CAS NO: 2783-72-4
• Molecular Formula: C₁₇H₁₅N₂S₂*I
• Molecular Weight: 438.3489
• Mol File: 2783-72-4.mol

Chemical Properties

• CAS DataBase Reference: 3-methyl-2-[(Z)-(3-methyl-1,3-benzothiazol-2(3H)-ylidene)methyl]-1,3-benzothiazol-3-ium iodide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-2-[(Z)-(3-methyl-1,3-benzothiazol-2(3H)-ylidene)methyl]-1,3-benzothiazol-3-ium iodide(2783-72-4)
• EPA Substance Registry System: 3-methyl-2-[(Z)-(3-methyl-1,3-benzothiazol-2(3H)-ylidene)methyl]-1,3-benzothiazol-3-ium iodide(2783-72-4)

Safety Data

• Hazardous Substances Data: 2783-72-4(Hazardous Substances Data)

Upstream product

• 14779-16-9 2-Imino-3-methylbenzothiazolin 
• 2038-15-5 2,3-dimethylbenzothiazolium methosulfate 
• 3595-73-1 2-(3-methyl-3H-benzothiazol-2-ylidenemethyl)-benzothiazole 
• 74-88-4 methyl iodide 
• 101291-76-3 2-(benzothiazol-2-ylmercapto-methylene)-3-methyl-2,3-dihydro-benzothiazole 
• 77-78-1 dimethyl sulfate 
• 16021-56-0 1,2,2-trimethyl-1,2-dihydroquinoline 
• 4329-95-7 3-Methylbenzothiazolium 2-sulfonate 
• 16768-72-2 1-methyl-2-(3-methyl-3H-benzothiazol-2-ylidenemethyl)-quinolinium; iodide 
• 2785-06-0 2,3-dimethylbenzothiazolium iodide 
• 38925-99-4 2,3-Dimethylbenzthiazoliummethosulfat 
• 120-75-2 2-Methylbenzothiazole 
• 27825-90-7 3-methyl-2-methylthiobenzothiazolium methylsulfate 
• 149-30-4 2-Mercaptobenzothiazole 

Downstream Products

• 13372-62-8 N-methyl-o-aminophenyl methyl sulphide 

Relevant articles and documents

RNA-targeting low-molecular-weight fluorophores for nucleoli staining: synthesis,in silicomodelling and cellular imaging

Herein we present our work on the synthesis, investigation of the photophysical properties, interactions with nucleic acids, molecular docking, and imaging application of three carbocyanine dyes. The described low-molecular-weight compounds were found to exhibit high resistance against photobleaching and showed promising optical properties as fluorescent labeling agents for ribonucleic acids. They form strong biocomplexes (log?Ks= 6.11-7.84) and revealed remarkable sensitivity towards RNA, reaching up to a 379 times increase of the emission signal when bound to AU-rich sequences. According to the score values obtained from the molecular docking studies, the compounds show strong binding affinity towards RNA macromolecules. All fluorophores exhibit significant cell tolerance since they were found to be 16 to 60 times less toxic against MRC5 cells (healthy human fibroblasts) compared to the conventional Thiazole Orange - TO. The IC50 concentrations for the compounds were calculated up to 40 μM in human fibroblasts MRC5, A549 adenocarcinomic human alveolar basal epithelial cells, the HCT116 human colon cancer cell line, and MDA-MB-231 adenocarcinoma cells. Analyzing the dyes for preferential cytotoxicity towards cancer cell lines in comparison to the normal human fibroblasts, we found a candidate exhibiting promising anticancer potential. Based on the selectivity (Si) towards cancer cells and more specifically against difficult to treat colon HCT116 carcinoma, we can suggest these small molecules as an interesting platform for further development. We have also demonstrated the efficiency of the carbocyanines as staining agents forin vivolabeling of human cells as well as microbial and eukaryotic cells.

2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE

The present invention pertains to certain 2-[3H-thiazol-2-ylidinemethyl]pyridine compounds and analogs thereof, which, inter alia, inhibit cell proliferation, treat cancer, etc., and more specifically to compounds of the following formula, wherein RA1, RA2, RA3, RA4, RB1, RB2, RNA, RNB, and X? are as defined herein: The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative conditions such as cancer, etc.